Christian Clark, MD
Gastroenterology · Tulsa, OKNPI 1649223710
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,805 of the $7,311 with a category attached, or 79.4%. 29 manufacturers reported payments, led by AbbVie at 38.3% of the total. Reporting peaked in 2021 at $2,469 and has fallen 76.1% since, to $590 in 2025.
Across 320 payments — averaging $22.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$619
- Olympus America Inc.$608
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$532
- Takeda Pharmaceuticals U.S.A., Inc.$514
- Pfizer$439
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$1,50021%
- Food & beverage$5,80579%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 86 | $2,798 |
| Johnson & Johnson | 43 | $619 |
| Olympus America Inc. | 32 | $608 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $532 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $514 |
| Pfizer | 26 | $439 |
| Ambu Inc. | 2 | $221 |
| Regeneron Healthcare Solutions, Inc. | 8 | $189 |
| Bristol Myers Squibb | 10 | $172 |
| Covidien LP | 2 | $161 |
| Gilead | 9 | $161 |
| Lilly USA, LLC | 5 | $130 |
| Daiichi Sankyo Inc. | 6 | $125 |
| Merck | 7 | $114 |
| Ferring Pharmaceuticals Inc. | 5 | $84 |
| Medtronic | 3 | $78 |
| Braintree Laboratories, Inc. | 4 | $63 |
| Sanofi | 3 | $53 |
| Madrigal Pharmaceuticals | 2 | $46 |
| Ipsen Biopharmaceuticals, Inc | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 1 | $35 |
| Intercept Pharmaceuticals, Inc. | 2 | $30 |
| Mylan Institutional Inc. | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Redhill Biopharma Inc. | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
| Boston Scientific | 1 | $11 |
| Micro-tech Endoscopy USA, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,311 in reported general payments places this provider in the 60th percentile of 133 gastroenterology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 69 | $11,354 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 61 | $8,361 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 51 | $6,358 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 18 | $2,890 |
| Mesalamine | 13 | $2,834 |
| Omeprazole | 29 | $886 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 47 | $786 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 13 | $750 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 19 | $332 |
| Pantoprazole Sodium | 51 | $307 |
| Azathioprine | 12 | $167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ferring Pharmaceuticals Inc.Clenpiq | $84 | $11,35469 claims |
| Braintree Laboratories, Inc.Suflave, Sutab | $63 | $9,24769 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $532 | $8,36161 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 133 gastroenterology providers in Oklahoma.
Other gastroenterology in Tulsa
- Jeffrey HuntTulsa$155K
- Harvey TatumTulsa$27K
- Roy ThompsonTulsa$16K
- Aaron FiekerTulsa$15K
- Vasudevan RaghuramanTulsa$14K
- William BriggsTulsa$14K
- Sheldon BergerTulsa$14K
- David MorrisTulsa$13K
- Patrick VolakTulsa$13K
- Matt BlankenshipTulsa$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.